Quick Answer
Lyell Immunopharma, Inc. reported Stockholders Equity of $248.20 million for the year ending 2025.
- Lyell Immunopharma, Inc. showed a decrease of -35.2% in Stockholders Equity from 2024 to 2025.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$150.83 million | Q2 2020: -$240.11 million | Q3 2020: -$266.64 million | Q1 2021: -$334.05 million | Q2 2021: $1.02 billion | Q3 2021: $986.47 million | Q1 2022: $881.25 million | Q2 2022: $868.04 million | Q3 2022: $820.03 million | Q1 2023: $783.83 million | Q2 2023: $736.86 million | Q3 2023: $697.57 million | Q1 2024: $603.16 million | Q2 2024: $566.50 million | Q3 2024: $530.70 million | Q1 2025: $336.52 million | Q2 2025: $298.92 million | Q3 2025: $329.12 million.
- Over the full 8 years of available data (2018 to 2025), Lyell Immunopharma, Inc.'s Stockholders Equity has grown by 29,100.2%.
- Historical annual values: Fiscal year 2025: $248.20 million | Fiscal year 2024: $382.82 million | Fiscal year 2023: $654.95 million | Fiscal year 2022: $833.25 million | Fiscal year 2021: $929.79 million | Fiscal year 2020: -$292.53 million | Fiscal year 2019: -$111.11 million | Fiscal year 2018: $850.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: